Company
Headquarters: North Chesterfield, VA, United States
Founded: 1994
Employees: 800
CEO: Mr. Mark Crossley
£1.41 Billion
GBP as of July 1, 2025
US$1.94 Billion
| Company | Market Cap (USD) |
|---|---|
| Lilly | $968.50 B |
| Johnson & Johnson | $499.57 B |
| AbbVie | $405.28 B |
| Roche | $332.12 B |
| UnitedHealth Group | $304.72 B |
Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders. The company's product pipeline focuses on treating opioid use disorder, addiction, and schizophrenia. It markets and promotes SUBLOCADE injection for subcutaneous use; and SUBOXONE sublingual film, SUBOXONE sublingual tablet, and SUBUTEX sublingual tablet, as well as sells legacy products that include Temgesic, Burpex, and Buprenex. The company is also involved in finance activities. It operates in approximately 40 countries worldwide. Indivior PLC has research collaboration agreement with Addex Therapeutics Ltd. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.
| Last Financial Reports Date | March 31, 2025 |
| Revenue TTM | £851.6 M |
| EBITDA | £280.0 M |
| Gross Profit TTM | £695.1 M |
| Profit Margin | -5.30% |
| Operating Margin | 25.56% |
| Quarterly Revenue Growth | -6.30% |
Indivior plc has the following listings and related stock indices.
Stock: LSE: INDV
Stock: FSX: 2IV
Stock: FSX: 2IVA
Stock: OTC: IZQVF
Subutex/Subuxone
Graham Hetherington, Chairman Mark Crossley, CEO